|Articles|August 1, 1999

Vascular Compliance: Clinical and Managed Care Issues
Volume 5
Issue 12 Suppl

Participating Faculty

Download PDF: Participating Faculty

Articles in this issue

about 27 years ago

Article

Introduction

about 27 years ago

Article

The Clinical Context of Vascular Compliance: Compromised Vascular Compliance as a Measure of Cardiovascular Risk

about 27 years ago

Article

Changes in Blood Pressure and Vascular Physiology: Markers for Vascular Disease

about 27 years ago

Article

Can Arterial Stiffness be Reversed? And If So, What are the Benefits?

about 27 years ago

Article

Perindopril: Clinical Profile of a Unique ACE Inhibitor

about 27 years ago

Article

Issues in Vascular Compliance

about 27 years ago

Article

Risk Stratification: A Key to Managing Hypertension in the Managed Care Setting

about 27 years ago

Article

Selected Abstracts

about 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Participating Faculty

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About the FDA's Peptide Reversal

Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial

FDA Approves First Orexin Agonist for Narcolepsy Type 1

Ochsner Health, Paradigm Health Partnership Expands Clinical Trial Access Across the Gulf South

A Multi-Country Needs Assessment on MCL and CLL Management